Patheon IncTSX: PTI

Patheon reports fourth quarter and full year 2008 results

· Issued by Patheon Inc via CNW
-   Q4 revenue increased 6.4% (approximately 8% in local currencies) over
    prior year
-   Full year revenue grew 13.1% (approximately 9% in local currencies)
    over prior year
-   Pharmaceutical Development Services (PDS) full year revenue increased
    20.4% over prior year
-   Puerto Rico continuing operations profitable in Q4
-   Planned shutdown of Carolina, Puerto Rico facility announced

TORONTO, Dec. 12 /CNW/ - Patheon (TSX:PTI) today announced its results for the fourth quarter ended October 31, 2008 with revenue of $172.1 million, 6.4% higher than last year (approximately 8% in local currencies), and EBITDA before repositioning expenses (hereafter referred to as EBITDA) of $24.8 million, 4.6% higher than last year. Net income for the quarter was $36.9 million vs. a net loss of $7.5 million in the prior year period, reflecting improved operating performance, reduced repositioning expenses and a $34.9 million one-time gain on the extinguishment of debt due to the previously announced JLL Preferred Share Agreement Amendment, discussed below.

"We are very pleased to close out fiscal 2008 with solid results across the business, including the achievement of a small profit from our Puerto Rico continuing operations in the fourth quarter. The turnaround in Puerto Rico is the result of a combination of cost reduction, improved operating discipline and higher production volumes from new and existing products," said Wes Wheeler, President and Chief Executive Officer of Patheon Inc. "strong revenue and margin growth for both the fourth quarter and full year 2008 are a clear indication of the hard work done to restructure and refocus our company."

"The decision to shut down Carolina during the first quarter of 2009 represents the last major restructuring step for the Company. We start 2009 as a new beginning for Patheon, with a solid balance sheet and a strong platform for future growth," said Wes Wheeler.

Fourth Quarter 2008 Operating Results from Continuing Operations

Consolidated revenue increased 6.4% (approximately 8% in local currencies) to $172.1 million over the prior year fourth quarter consolidated revenue of $161.8 million. Commercial Manufacturing revenues increased 4.6% year-over-year to $135.3 million, driven by a combination of recently signed business and growth in volumes of existing business in all regions. Pharmaceutical Development Services (PDS) fourth quarter 2008 revenues increased 13.3% year-over-year to $36.8 million, supported by strong growth in the Canadian, Italian and US development centers.

Consolidated EBITDA was $24.8 million, compared with $23.7 million in the same period last year. The growth in EBITDA this quarter would have been more pronounced had it not been for differences in non-cash net foreign exchange adjustments related to the historic accounting treatment of the Company's convertible preferred shares. This quarter included a $2.3 million foreign exchange loss compared to a $7.5 million gain in the same period last year. This foreign exchange exposure was eliminated in September, 2008 due to the JLL Preferred Share Agreement Amendment. Additionally, the 2007 results included a one-time curtailment gain of $4.3 million related to changes in Company benefit plans. Absent these non-recurring items, EBITDA in the recent quarter was 129% higher than the same period last year

EBITDA from the North American commercial manufacturing operations increased by $6.9 million, driven by a significant improvement in the Puerto Rico operations, where the Company achieved its break-even target for the fourth quarter of 2008 by generating a modest profit. Canadian EBITDA increased over the same period in 2007, offset in part by Cincinnati due to a change in product in mix. The 2007 results reflected the one-time actuarial gains recorded in 2007. European commercial manufacturing operation EBITDA increased by $8.3 million due to improved margins in the Swindon and Bourgoin operations.

EBITDA for the global PDS operations was $12.7 million in the fourth quarter of 2008, $3.4 million higher than the same period in 2007. This growth in profitability was derived from increased revenues in both regions, new business in Japan and better overhead absorption.

Full Year 2008 Operating Results from Continuing Operations

Consolidated revenue grew 13.1% year-over-year (approximately 9% in local currencies) to $717.3 million vs. $634.1 million for 2007. Consolidated EBITDA before repositioning expenses (hereafter referred to as EBITDA margin) was $82.6 million reflecting an EBITDA margin of 11.5% for 2008, compared with $84.1 million for an EBITDA margin of 13.3% in 2007. The 2008 results included non-cash net foreign exchange losses related to the preferred shares of $6.4 million compared to a non-cash gain of $12.3 million for 2007. The 2008 results also reflect additional costs incurred in connection with recruiting executive and senior management positions, consulting fees related to restructuring and productivity enhancement programs, and severance costs.

Net loss for the year was $1.4 million vs. a loss of $94.6 million in the prior year, reflecting improved operating performance, reduced losses from discontinued operations and a $34.9 million one-time gain on the extinguishment of debt due to the previously announced JLL Preferred Share Agreement Amendment, discussed below.

Commercial manufacturing revenues increased 11.5% year-over-year to $577.7 million reflecting growth from the existing customer base in the European and Canadian and Puerto Rico operations. EBITDA from the commercial manufacturing operations was $77.5 million, 45% or 24.1 million higher than in 2007.

PDS revenues grew 20.4% year-over-year to $139.5 million from $115.9 million reflecting continued broad based growth in all regions. EBITDA from the global PDS operations was $42.1 million compared to $30.4 million in 2007. This reflected the benefit of volume gains in all regions.

Restructuring Activities

Patheon believes that the majority of the Company's restructuring expenses related to continuing operations have now been recognized. Repositioning expenses were $19.9 million for 2008 compared to $14.5 million for 2007 attributable to changes in executive and senior management, the previously announced workforce reduction in Swindon and the on-going York Mills/Whitby consolidation and restructuring of the Puerto Rico operations. Costs related to an early retirement program at Cincinnati were included in operating costs, as noted above.

Convertible Preferred Shares

As previously announced on September 19, 2008, the Company completed an agreement with JLL Patheon Holdings, LLC (JLL) under which JLL waived its right to the mandatory redemption provision of the Company's convertible preferred shares. The change in terms resulted in a deemed repayment of the debt and equity components of the convertible preferred shares. The Company recognized in the fourth quarter a non-cash gain of approximately $35 million on the deemed repayment of the debt component, which was higher than originally estimated due to changes in market valuations and comparables. The agreement resulted in a net increase in shareholders' equity of approximately $153 million.

Additional details on the Agreement can be found in the Company's year ended October 31, 2008 MD&A.

Subsequent Events

Subsequent to the end of fiscal 2008, the Company decided to shut down its Carolina, Puerto Rico facility if a timely sale could not be completed. The Carolina facility is classified as a discontinued operation, with related assets and liabilities being classified as held for sale as of October 31, 2008. Serious interest has been shown by strategic buyers and negotiations have occurred with multiple parties. However, the Company has determined that eliminating the cash drain of Carolina through an immediate shutdown outweighs the risk of the sale process taking an extended period of time to complete and/or ultimately being unsuccessful. Assuming that a timely sale cannot be completed, the Company expects to close the facility by the end of the first quarter of 2009 and estimates that severance and other closure costs will be approximately $3.0 million.

On December 8, 2008 JLL announced in a press release its intention to make an unsolicited offer to acquire any or all the outstanding restricted voting shares of Patheon that it does not already own at a price of USD $2.00 per share in cash which is equivalent to C$2.54 per share based on the exchange rate on December 5, 2008. JLL holds convertible preferred shares of the Company, which when converted and taken together with its holdings of restricted voting shares, would represent approximately 29% of the restricted voting shares of the Company.

Patheon's Board of Directors has appointed a special committee of independent directors, none of whom is associated with JLL to review and evaluate the proposed unsolicited bid from JLL, and make recommendations to the Board of Directors. Patheon's Board of Directors will advise shareholders of its recommendation with respect to this proposed bid in due course and until such time shareholders have been advised to take no action with respect to the bid. The Company remains very confident in its business plan and continues to run its business as usual.

Outlook

Revenues are expected to decline slightly for the first quarter of fiscal 2009 versus the same quarter last year due to strengthening of the US dollar. EBITDA in the first quarter is expected to be comparable with the first quarter of 2008, reflecting the normal seasonality in the business due to the December holiday shutdowns and customer purchasing practices around the calendar yearend. These forecasts are subject to the strength of the U.S. dollar relative to the Canadian dollar, euro and pounds sterling.

These expectations are based on internal management forecasts, which in the case of the revenue forecasts, are based on client purchase orders and forecasts of anticipated demand and other factors. These internal management forecasts were prepared for internal planning purposes and may not be appropriate for forecasting future financial results or for other purposes.

Management's Discussion and Analysis

This release should be read in conjunction with Patheon Inc.'s year ended October 31, 2008 MD&A dated December 12, 2008 (available at http://www.patheon.com) which is incorporated by reference in this release, and filed by Patheon Inc. with the Canadian securities commission.

ABOUT PATHEON

Patheon Inc. (TSX:PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies.

Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic(TM) programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API.

Patheon's integrated development and manufacturing network of 10 facilities, and 6 development centers across North America and Europe, strives to ensure that customer products can be launched with confidence anywhere in the world.

Caution Concerning Forward-Looking Statements

This news release contains forward-looking statements which reflect management's expectations regarding Patheon's future growth, results of operations, performance (both operational and financial) and business prospects and opportunities. Where possible words such as ''plans,'' "expects" or "does not expect," "budget," "forecasts," "anticipates" or "does not anticipate," "believes," "intends" and similar expressions or statements that certain actions, events or results "may," "could," "would," "might" or "will" be taken, occur or be achieved, have been used to identify these forward-looking statements. Although the forward-looking statements contained in this news release reflect management's current assumptions based upon information currently available to management and based upon that which management believes to be reasonable assumptions, Patheon cannot be certain that actual results will be consistent with these forward-looking statements. Current material assumptions relate to foreign exchange rates, customer volumes and regulatory compliance. A number of factors could cause actual results, performance, or achievements to differ materially from the results expressed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Forward-looking statements necessarily involve significant known and unknown risks, assumptions and uncertainties that may cause Patheon's actual results, performance, prospects and opportunities in future periods to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things: international operations and foreign currency fluctuation; customer demand for Patheon's services; regulatory matters affecting manufacturing and pharmaceutical development services; exposure to complex production issues; substantial financial leverage; interest rate risks; potential environmental, health and safety liabilities; credit and customer concentration; competition; rapid technological change; product liability claims; intellectual property; significant shareholder; supply arrangements; pension plans; derivative financial instruments; international operations; and dependence upon key management personnel and executives. Although Patheon has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, as noted above, readers should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date of this news release and, except as required by law, Patheon assumes no obligation to update or revise them to reflect new events or circumstances.

Webcast Conference Call with Analysts

Patheon Inc. will host a webcast conference call with financial analysts on its fourth quarter and full year 2008 results on Friday, December 12, 2008 at 10:00 a.m. (Eastern Time). The call will begin with a brief presentation, followed by a question-and-answer period with investment analysts. Interested parties are invited to access the live call, via telephone, in listen-only mode, at (416) 644-3414 (Toronto and International) or toll free at (800) 733-7560 (U.S., including Puerto Rico). Listeners are encouraged to dial in five to 15 minutes in advance to avoid delays. A live audio webcast will also be available via the web at www.patheon.com. An archived version of the Q4 webcast will be available on www.patheon.com for three months.

Patheon Inc.
Consolidated Statements of Income (Loss)

                                Three months ended           Years ended
                                        October 31,           October 31,
                                   2008       2007       2008       2007
---------------------------------------------------- --------------------
(in thousands of U.S. dollars,
 except income (loss) per share)      $          $          $          $
--------------------------------------------------- ---------------------

Revenues                        172,106    161,821    717,251    634,146
Cost of goods sold              130,818    126,890    562,370    502,738
                              --------------------- ---------------------
Gross profit                     41,288     34,931    154,881    131,408
Selling, general and
 administrative expenses         30,022     28,069    121,277     97,525
Repositioning expenses            2,567      6,336     19,899     14,467
                              --------------------- ---------------------
Operating income                  8,699        526     13,705     19,416
Interest expense, net             6,672      7,460     30,789     29,119
Foreign exchange gain            (1,630)    (5,828)    (1,448)    (8,921)
Refinancing expenses                  -          -          -     13,471
Foreign exchange loss on
 foreign operations                   -          -          -        858
(Gain) loss on sale of
 fixed assets                       134          -       (282)         -
Gain on extinguishment of debt  (34,934)         -    (34,934)         -
                              --------------------- ---------------------
Income (loss) from continuing
 operations before income taxes  38,457     (1,106)    19,580    (15,111)
Provision for (recovery of)
 income taxes                    (2,866)     4,771      1,478     19,657
                              --------------------- ---------------------
Income (loss) from continuing
 operations                      41,323     (5,877)    18,102    (34,768)
Loss from discontinued
 operations                      (4,419)    (1,645)   (19,543)   (59,833)
                              --------------------- ---------------------
Net income (loss) for
 the period                      36,904     (7,522)    (1,441)   (94,601)
Dividends on convertible
 preferred shares                 1,463          -      1,463          -
                              --------------------- ---------------------
Net income (loss) attributable
 to restricted voting
 shareholders                    35,441     (7,522)    (2,904)   (94,601)
                              --------------------- ---------------------
                              --------------------- ---------------------

Basic and diluted earnings
 (loss) per share
  From continuing operations      $0.44     ($0.06)     $0.18     ($0.37)
  From discontinued operations   ($0.05)    ($0.02)    ($0.21)    ($0.65)
                              --------------------- ---------------------
                                  $0.39     ($0.08)    ($0.03)    ($1.02)
                              --------------------- ---------------------



Patheon Inc.
Consolidated Balance Sheets
(in thousands of U.S. dollars)
As of October 31

                                                         2008       2007
                                                            $          $
-------------------------------------------------------------------------
ASSETS
Current
Cash and cash equivalents                              20,248     30,557
Accounts receivable                                   141,224    127,691
Inventories                                            66,385     85,991
Prepaid expenses and other                              7,462     11,887
Assets held for sale                                    1,292     16,151
-------------------------------------------------------------------------
Total current assets                                  236,611    272,277
-------------------------------------------------------------------------

Capital assets                                        428,495    479,682
Intangible assets                                       4,886      6,770
Deferred costs                                          5,325      8,878
Future tax assets                                      34,719     31,039
Goodwill                                                2,869      3,658
Investments                                             1,748        946
Assets held for sale                                    1,930     26,367
-------------------------------------------------------------------------
Total assets                                          716,583    829,617
-------------------------------------------------------------------------
-------------------------------------------------------------------------

LIABILITIES AND SHAREHOLDERS' EQUITY
Current
Bank indebtedness                                       8,963      8,224
Accounts payable and accrued liabilities              174,931    159,335
Income taxes payable                                    2,615      4,684
Current portion of long-term debt                      10,220     11,719
Liabilities related to assets held for sale                17      7,743
-------------------------------------------------------------------------
Total current liabilities                             196,746    191,705
-------------------------------------------------------------------------

Long-term debt                                        200,460    203,615
Deferred revenues                                      22,496     25,994
Future tax liabilities                                 39,121     47,397
Convertible preferred shares - debt component               -    139,916
Other long-term liabilities                            16,371     22,069
Liabilities related to assets held for sale                14      1,736
-------------------------------------------------------------------------
Total liabilities                                     475,208    632,432
-------------------------------------------------------------------------

Shareholders' equity
Convertible preferred shares - equity component       149,168     15,925
Restricted voting shares                              393,523    391,967
Contributed surplus                                     6,663      4,049
Deficit                                              (304,065)  (286,250)
Accumulated other comprehensive income (loss)          (3,914)    71,494
-------------------------------------------------------------------------
Total shareholders' equity                            241,375    197,185
-------------------------------------------------------------------------
Total liabilities and shareholders' equity            716,583    829,617
-------------------------------------------------------------------------
-------------------------------------------------------------------------



Patheon Inc.
Consolidated Statements of Cash Flows
(in thousands of U.S. dollars)
                                Three months ended            Year ended
                                        October 31,           October 31,
                                   2008       2007       2008       2007
-------------------------------------------------------------------------
(in thousands of U.S. dollars)        $          $          $          $
-------------------------------------------------------------------------
Operating activities
  Net income (loss) from
   continuing operations         41,323     (5,877)    18,102    (34,768)
  Add (deduct) charges to
   operations not requiring a
   current cash payment
    Depreciation and
     amortization                12,291     10,994     47,594     41,343
    Foreign exchange loss
     (gain) on debt               2,298     (7,541)     7,015    (12,331)
    Foreign exchange loss on
     foreign operations               -          -          -        858
    Accreted interest on
     convertible preferred
     shares                       2,164      3,573     13,453      7,054
    Gain on extinguishment
     of debt                    (34,934)         -    (34,934)         -
    Other non-cash interest         146        151        567      1,657
    Employee future benefits,
     net of contributions        (1,287)    (5,169)    (3,165)    (4,846)
    Future income taxes          (3,667)     1,426    (12,461)     4,572
    Amortization of deferred
     revenues                      (380)      (505)    (1,893)    (2,021)
    Stock-based compensation
     expense                        499         52      2,614        220
    Other                          (482)     1,065       (414)     1,867
                              --------------------- ---------------------
                                 17,971     (1,831)    36,478      3,605
  Net change in non-cash
   working capital balances
   related to continuing
   operations                     5,305     18,812     (3,644)    (8,903)
  Increase in deferred revenues     582          8      2,683      2,065
                              --------------------- ---------------------
  Cash provided by (used in)
   operating activities of
   continuing operations         23,858     16,989     35,517     (3,233)
  Cash provided by (used in)
   operating activities of
   discontinued operations       (2,530)      (816)    (9,075)    14,824
                              --------------------- ---------------------
Cash provided by operating
 activities                      21,328     16,173     26,442     11,591
                              --------------------- ---------------------
Investing activities
  Additions to capital assets   (21,752)   (14,548)   (55,802)   (35,148)
  Proceeds on sale of
   capital assets                    87          -     12,176          -
  Net increase in investments        (4)       (25)    (1,315)      (202)
  Increase in deferred
   pre-operating costs                -       (832)         -     (3,659)
                              --------------------- ---------------------
  Cash used in investing
   activities of continuing
   operations                   (21,669)   (15,405)   (44,941)   (39,009)
  Cash provided by (used in)
   investing activities of
   discontinued operations           (8)      (137)    10,431       (929)
                              --------------------- ---------------------
Cash used in investing
 activities                     (21,677)   (15,542)   (34,510)   (39,938)
                              --------------------- ---------------------
Financing activities
  Increase (decrease) in bank
   indebtedness                  (8,605)    (4,230)     3,196      3,532
  Increase in long-term debt     16,504     15,456     40,326    198,108
  Repayment of long-term debt   (14,918)   (17,278)   (38,902)  (336,883)
  Issue of convertible
   preferred shares                   -          -          -    150,000
  Convertible preferred share
   issue cost - equity
   component                       (269)         -       (269)    (1,213)
  Issue of restricted voting
   shares                             3          -        431         24
  Repurchase of restricted
   voting shares                      -     (8,778)         -     (8,778)
                              --------------------- ---------------------
  Cash provided by financing
   activities of continuing
   operations                    (7,285)   (14,830)     4,782      4,790
  Cash used in financing
   activities of discontinued
   operations                        (1)      (102)      (180)      (569)
                              --------------------- ---------------------
Cash provided (used) by
 financing activities            (7,286)   (14,932)     4,602      4,221
                              --------------------- ---------------------
Effect of exchange rate changes
 on cash and cash equivalents    (6,170)     4,362     (6,843)     3,960
                              --------------------- ---------------------
Net decrease in cash and cash
 equivalents during the period  (13,805)    (9,939)   (10,309)   (20,166)
Cash and cash equivalents,
 beginning of period             34,054     40,496     30,557     50,723
                              --------------------- ---------------------
Cash and cash equivalents,
 end of period                   20,248     30,557     20,248     30,557
                              --------------------- ---------------------
                              --------------------- ---------------------

%SEDAR: 00001700E

Patheon Inc on 6ix

Story so far

Earlier from Patheon

Later from Patheon

All Patheon news releases